Abbreviation · Organisation
SEGM
Society for Evidence-Based Gender Medicine — international network of clinicians and researchers.
2 min read · updated May 2026
SEGM is an international network of clinicians, researchers and professors founded in 2019 by physicians concerned about the lack of evidence for standard transition care in young people. The network publishes systematic reviews, archives international policy, and tracks clinical evidence.
SEGM played an important role as a source for the Cass Review and for policy changes in Scandinavian countries.
Critical Analysis
SEGM is labelled "anti-trans" by activist healthcare bodies such as WPATH. The network, however, consists solely of scientifically published physicians and researchers, and publishes peer-reviewed material. The actual objections are always substantive: lack of evidence for puberty blockers, inadequate diagnostics, absent follow-up. To call SEGM "anti-trans" is not to refute a claim — it is to forbid it.
The Political Function of the Abbreviation
An abbreviation like SEGM is not a linguistic invention but a political instrument. Those who use it simultaneously signal acceptance of the accompanying ideological framework: identity over biology, self-declaration over diagnosis, language over reality. Those who refuse to go along are accused of being outdated or hateful.
Resistance to that pressure does not come from conservative quarters alone. Lesbian organisations, sports federations, women's rights organisations and clinicians are pushing back against the shifting of categorical boundaries. The abbreviation itself is often defended on the grounds of inclusion, but in practice it compels the abandonment of categories that are precisely protective — for women, for lesbians, for children.
Medical Context and the Evidence
The medical side of the debate has shifted entirely within just a few years. The Cass Review (2024) found that the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England consequently halted routine prescribing. SBU (Sweden, 2022), COHERE (Finland, 2020), UKOM (Norway, 2023) and NICE (UK, 2020) reached the same conclusion.
In the communications of organisations that embrace SEGM and related terms, these reassessments are almost always absent. The impression of settled science is maintained by silence about the Cass Review and the Scandinavian reversal. The WPATH Files (2024) showed that even within WPATH, clinicians harbour uncertainty about informed consent for minors.
Implications for Public Debate
Expanding abbreviations is not without cost. Each new letter carries a claim to recognition in law, education and healthcare. Without evidence for the underlying category, policy is made as though that evidence exists. Those who ask questions receive not substantive answers but moral condemnation.
Language drives policy. To accept the abbreviation is implicitly to accept the claim that all the identities it contains are equally valid and scientifically grounded. That is a political claim, not a linguistic one. Criticism of an abbreviation is not criticism of individuals — it is criticism of a framework that is being placed ever further beyond the reach of debate.
International Reassessment
Several national health authorities have in recent years moved away from the gender-affirming model for minors. The common denominator: evidence for lasting benefits is absent, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England halted routine prescribing of puberty blockers outside a research setting.
SBU — Sweden (2022). The Swedish agency for medical assessment (SBU) and Karolinska University Hospital discontinued puberty blockers and hormones for minors outside a research setting. Reason: evidence for efficacy and safety is lacking.
NICE — United Kingdom (2020). Two evidence reviews by NICE (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). Finland's Council for Choices in Health Care revised its protocol: psychotherapy as first-line treatment, medical transition in minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). Norway's UKOM classified gender healthcare for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians show acknowledgement that informed consent in minors is problematic and that serious side effects (bone density, fertility, cognitive development) are insufficiently communicated.